A Phase 3 interventional study of teduglutide in Short Bowel Syndrome, sponsored by Shire. Completed at 19 sites in 2 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-09.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 8th largest by enrollment, is the only one that started in 2013, is one of 16 in phase 3, and was the 7th registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 4 mo–17 yrs
By country, each count listing its studies:
teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 1 Year to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2013.
This study's enrollment of 42 is above the median of 21 across 108 interventional studies indexed under Short Bowel Syndrome.
Median enrollment 20 across the 20 interventional studies. Of the 18 that completed or were terminated, 16 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 6 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
26 studies in Short Bowel Syndrome by Takeda: 1 open now, 3 under way, 1 of them phase 3. Of 23 finished, 16 (70%) have results posted.
Among the 26 studies in Short Bowel Syndrome by Takeda, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2013, is one of 17 in phase 3, and was the 7th registered.
Takeda’s Short Bowel Syndrome studies by the year they started, since 2004.
1 of the studies testing teduglutide in Short Bowel Syndrome that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06973304Phase 3TakedaA Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | 2027-02-10 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 26 in Short Bowel Syndrome:
This tab as a report to print or save as PDF → With an account.
This will be an open label, 4-cohort study. Non-randomized subjects will receive teduglutide in each of the 3 active cohorts. An attempt will be made to enroll additional subjects into an observational cohort who will receive standard of care. Three doses of teduglutide are to be investigated for 12 weeks. All subjects will be screened prior to the start of treatment (SOT) to establish baseline characteristics including safety, eligibility and nutritional support parameters.
Key Inclusion Criteria:
Key Exclusion Criteria:
Open label teduglutide, subcutaneously injected.
Drug: teduglutide
Open label intervention. Each subject will be assigned to receive 0.0125, 0.025, or 0.05 mg/kg/day for the duration of the study
Percent Change in Parenteral Support [Parenteral Nutrition (PN)/Intravenous (IV)] Volume at Week 12
Percent change in PN/IV from the Baseline Visit to Week 12 Visit.
Time frame: Baseline, Week 12
Percent Change in Parenteral Support (PN/IV) Volume at End of Treatment
Percent change in PN/IV from the Baseline Visit to End of Treatment Visit.
Time frame: Baseline, End of Treatment
Percent Change in Parenteral Support (PN/IV) Volume at Week 16
Percent change in PN/IV from the Baseline Visit to Week 16 Visit.
Time frame: Baseline, Week 16
Absolute Change in Parenteral Support (PN/IV) Volume at Week 12
Absolute change in PN/IV from the Baseline Visit to Week 12 Visit.
Time frame: Baseline, Week 12
Absolute Change in Parenteral Support (PN/IV) Volume at End of Treatment
Absolute change in PN/IV from the Baseline Visit to End of Treatment Visit.
Time frame: Baseline, End of Treatment
Absolute Change in Parenteral Support (PN/IV) Volume at Week 16
Absolute change in PN/IV from the Baseline Visit to Week 16 Visit.
Time frame: Baseline, Week 16
Percent Change in Enteral Support (EN) Volume From Baseline at Week 12
Percent change in enteral support requirements at Week 12 (liters/week)
Time frame: Baseline, Week 12
Percent Change in Enteral Support (EN) Volume From Baseline at Week 16
Percent change in enteral support requirements at Week 16 (liters/week)
Time frame: Baseline, Week 16
Absolute Change in Enteral Support (EN) Volume From Baseline at Week 12
Absolute change in enteral support requirements at Week 12 (liters/week)
Time frame: Baseline, Week 12
Absolute Change in Enteral Support (EN) Volume From Baseline at Week 16
Absolute change in enteral support requirements at Week 16 (liters/week)
Time frame: Baseline, Week 16
| Milestone | Standard of Care | Teduglutide 0.0125 mg/kg/Day | Teduglutide 0.025 mg/kg/Day | Teduglutide 0.05 mg/kg/Day |
|---|---|---|---|---|
| Started | 5 | 8 | 14 | 15 |
| Treated | 5 | 8 | 14 | 15 |
| Completed | 5 | 7 | 14 | 14 |
| Not completed | 0 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Withdrew: Protocol non-compliance | 0 | 1 | 0 | 0 |
Percent change in PN/IV from the Baseline Visit to Week 12 Visit.
| percent change | Standard of Care | Teduglutide 0.0125 mg/kg/Day | Teduglutide 0.025 mg/kg/Day | Teduglutide 0.05 mg/kg/Day |
|---|---|---|---|---|
| Percent Change in Parenteral Support [Parenteral Nutrition (PN)/Intravenous (IV)] Volume at Week 12 | 7.38 ± 12.756 | -9.95 ± 21.625 | -37.34 ± 26.422 | -39.11 ± 40.792 |
Percent change in PN/IV from the Baseline Visit to End of Treatment Visit.
| percent change | Standard of Care | Teduglutide 0.0125 mg/kg/Day | Teduglutide 0.025 mg/kg/Day | Teduglutide 0.05 mg/kg/Day |
|---|---|---|---|---|
| Percent Change in Parenteral Support (PN/IV) Volume at End of Treatment | 7.38 ± 12.756 | -8.60 ± 20.380 | -35.61 ± 26.198 | -36.50 ± 40.585 |
Percent change in PN/IV from the Baseline Visit to Week 16 Visit.
| percent change | Standard of Care | Teduglutide 0.0125 mg/kg/Day | Teduglutide 0.025 mg/kg/Day | Teduglutide 0.05 mg/kg/Day |
|---|---|---|---|---|
| Percent Change in Parenteral Support (PN/IV) Volume at Week 16 | 3.92 ± 16.616 | -11.25 ± 21.196 | -33.85 ± 27.017 | -31.80 ± 39.264 |
Absolute change in PN/IV from the Baseline Visit to Week 12 Visit.
| Liters/week | Standard of Care | Teduglutide 0.0125 mg/kg/Day | Teduglutide 0.025 mg/kg/Day | Teduglutide 0.05 mg/kg/Day |
|---|---|---|---|---|
| Absolute Change in Parenteral Support (PN/IV) Volume at Week 12 | 0.43 ± 0.746 | -0.50 ± 0.910 | -2.78 ± 1.985 | -2.57 ± 3.564 |
Percent change in enteral support requirements at Week 12 (liters/week)
| percent change | Standard of Care | Teduglutide 0.0125 mg/kg/Day | Teduglutide 0.025 mg/kg/Day | Teduglutide 0.05 mg/kg/Day |
|---|---|---|---|---|
| Percent Change in Enteral Support (EN) Volume From Baseline at Week 12 | 16.82 ± 14.921 | 23.50 ± 22.060 | 50.93 ± 61.416 | 57.96 ± 44.953 |
Percent change in enteral support requirements at Week 16 (liters/week)
| percent change | Standard of Care | Teduglutide 0.0125 mg/kg/Day | Teduglutide 0.025 mg/kg/Day | Teduglutide 0.05 mg/kg/Day |
|---|---|---|---|---|
| Percent Change in Enteral Support (EN) Volume From Baseline at Week 16 | 52.06 ± 66.194 | 60.30 | 43.98 ± 78.599 | 58.93 ± 63.927 |
Absolute change in enteral support requirements at Week 12 (liters/week)
| Liters/week | Standard of Care | Teduglutide 0.0125 mg/kg/Day | Teduglutide 0.025 mg/kg/Day | Teduglutide 0.05 mg/kg/Day |
|---|---|---|---|---|
| Absolute Change in Enteral Support (EN) Volume From Baseline at Week 12 | 0.69 ± 0.715 | 2.67 ± 4.412 | 2.64 ± 3.220 | 0.97 ± 1.127 |
Absolute change in enteral support requirements at Week 16 (liters/week)
| Liters/week | Standard of Care | Teduglutide 0.0125 mg/kg/Day | Teduglutide 0.025 mg/kg/Day | Teduglutide 0.05 mg/kg/Day |
|---|---|---|---|---|
| Absolute Change in Enteral Support (EN) Volume From Baseline at Week 16 | 0.84 ± 0.624 | 4.56 ± 5.384 | 2.47 ± 3.403 | 0.91 ± 0.968 |
Absolute change in PN/IV from the Baseline Visit to End of Treatment Visit.
| Liters/week | Standard of Care | Teduglutide 0.0125 mg/kg/Day | Teduglutide 0.025 mg/kg/Day | Teduglutide 0.05 mg/kg/Day |
|---|---|---|---|---|
| Absolute Change in Parenteral Support (PN/IV) Volume at End of Treatment | 0.43 ± 0.746 | -0.43 ± 0.864 | -2.73 ± 1.916 | -2.4 ± 3.498 |
Absolute change in PN/IV from the Baseline Visit to Week 16 Visit.
| Liters/week | Standard of Care | Teduglutide 0.0125 mg/kg/Day | Teduglutide 0.025 mg/kg/Day | Teduglutide 0.05 mg/kg/Day |
|---|---|---|---|---|
| Absolute Change in Parenteral Support (PN/IV) Volume at Week 16 | 0.17 ± 1.027 | -0.56 ± 0.885 | -2.56 ± 1.917 | -1.99 ± 3.092 |
Collected over Adverse event data were collected from the first patient consent signed through last subject last visit for a duration of 421 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Standard of Care | — | 3/5 (60%) | 5/5 (100%) |
| Teduglutide 0.0125 mg/kg/Day | — | 3/8 (37.5%) | 8/8 (100%) |
| Teduglutide 0.025 mg/kg/Day | — | 6/14 (42.9%) | 14/14 (100%) |
| Teduglutide 0.05 mg/kg/Day | — | 8/15 (53.3%) | 15/15 (100%) |
| Event | Standard of Care | Teduglutide 0.0125 mg/kg/Day | Teduglutide 0.025 mg/kg/Day | Teduglutide 0.05 mg/kg/Day |
|---|---|---|---|---|
| PyrexiaGeneral disorders | 2/5 | 0/8 | 1/14 | 3/15 |
| Central line infectionInfections and infestations | 0/5 | 0/8 | 3/14 | 1/15 |
| Catheter related complicationGeneral disorders | 1/5 | 0/8 | 2/14 | 1/15 |
| FungaemiaInfections and infestations | 1/5 | 0/8 | 0/14 | 0/15 |
| Gastroenteritis viralInfections and infestations | 1/5 | 0/8 | 0/14 | 0/15 |
| Viral infectionInfections and infestations | 1/5 | 0/8 | 0/14 | 0/15 |
| Adenovirus infectionInfections and infestations | 0/5 | 1/8 | 0/14 | 0/15 |
| Catheter related infectionInfections and infestations | 0/5 | 1/8 | 0/14 | 0/15 |
| InfluenzaInfections and infestations | 0/5 | 1/8 | 0/14 | 0/15 |
| Abdominal DistensionGastrointestinal disorders | 0/5 | 0/8 | 1/14 | 0/15 |
| Event | Standard of Care | Teduglutide 0.0125 mg/kg/Day | Teduglutide 0.025 mg/kg/Day | Teduglutide 0.05 mg/kg/Day |
|---|---|---|---|---|
| Gastrointestinal stoma complicationInjury, poisoning and procedural complications | — | 0/1 | 0/1 | 1/1 |
| VomitingGastrointestinal disorders | 0/5 | 0/8 | 5/14 | 7/15 |
| PyrexiaGeneral disorders | 2/5 | 0/8 | 2/14 | 7/15 |
| Upper respiratory tract infectionInfections and infestations | 2/5 | 2/8 | 4/14 | 4/15 |
| Blood bicarbonate decreasedInvestigations | 2/5 | 1/8 | 1/14 | 3/15 |
| Catheter related complicationGeneral disorders | 1/5 | 3/8 | 4/14 | 2/15 |
| Abdominal painGastrointestinal disorders | 1/5 | 1/8 | 1/14 | 4/15 |
| FatigueGeneral disorders | 0/5 | 0/8 | 1/14 | 4/15 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/5 | 1/8 | 2/14 | 4/15 |
| FlatulenceGastrointestinal disorders | 0/5 | 2/8 | 1/14 | 0/15 |
| Age, Continuous(years) | Standard of Care | Teduglutide 0.0125 mg/kg/Day | Teduglutide 0.025 mg/kg/Day | Teduglutide 0.05 mg/kg/Day | Total |
|---|---|---|---|---|---|
| Mean | 2.2 ± 0.45 | 5.1 ± 4.55 | 4.6 ± 3.43 | 4.5 ± 3.16 | 4.7 ± 3.5 |
| Age, Customized(Participants) | Standard of Care | Teduglutide 0.0125 mg/kg/Day | Teduglutide 0.025 mg/kg/Day | Teduglutide 0.05 mg/kg/Day | Total |
|---|---|---|---|---|---|
| 1 to 3 years | 5 | 4 | 6 | 7 | 22 |
| 4 to 12 years | 0 | 3 | 7 | 7 | 17 |
| 13 to 17 years | 0 | 1 | 1 | 1 | 3 |
| Sex: Female, Male(Participants) | Standard of Care | Teduglutide 0.0125 mg/kg/Day | Teduglutide 0.025 mg/kg/Day | Teduglutide 0.05 mg/kg/Day | Total |
|---|---|---|---|---|---|
| Female | 2 | 2 | 3 | 7 | 14 |
| Male | 3 | 6 | 11 | 8 | 28 |
| Region of Enrollment(Participants) | Standard of Care | Teduglutide 0.0125 mg/kg/Day | Teduglutide 0.025 mg/kg/Day | Teduglutide 0.05 mg/kg/Day | Total |
|---|---|---|---|---|---|
| United States | 5 | 8 | 14 | 12 | 39 |
| United Kingdom | 0 | 0 | 0 | 3 | 3 |
Ran from Nov 2013 to primary completion in Jan 2015, 13 months.
Results were first posted in Sep 2015, 8 months after primary completion.
Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 13 months is below that.
Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teduglutide